Physician profile
Pradeep Kulkarni
NPI 1710933148
$709.26
in general payments reported to CMS, 2019-2025
11 companies · $97.48 in 2025
The $97.48 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $212 · 2020: $72.76 · 2022: $156 · 2023: $56.90 · 2024: $114 · 2025: $97.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $268.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $116.23 | 2022 | |
| Abbvie INC. | $113.91 | 2024 | |
| Janssen Pharmaceuticals, INC | $103.15 | 2019-2020 | |
| Novo Nordisk INC | $97.48 | 2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $84.33 | 2019-2020 | |
| Pfizer INC. | $66.57 | 2020-2023 | |
| Boston Scientific Corporation | $58.72 | 2022-2023 | Watchman Access System |
| Astrazeneca Pharmaceuticals LP | $28.44 | 2019 | |
| Vifor Pharma, INC. | $18.35 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.29 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $10.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pradeep Kulkarni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.